International Edition
Latest News
Health

UK Study: Medical Cannabis Improves Insomnia Over 24 Months

A UK study published in Neuropsychopharmacology Reports shows medical cannabis improves insomnia quality over a 24-month period. Longitudinal data published in Neuropsychopharmacology Reports shows that individuals dealing with insomnia achieve lasting enhancements in their sleep quality following the…

UK Study: Medical Cannabis Improves Insomnia Over 24 Months

A UK study published in Neuropsychopharmacology Reports shows medical cannabis improves insomnia quality over a 24-month period.

Longitudinal data published in Neuropsychopharmacology Reports shows that individuals dealing with insomnia achieve lasting enhancements in their sleep quality following the use of medical cannabis preparations.

British researchers assessed the use of botanical cannabis, oil extracts, and other authorized formulations in 126 patients enrolled in the UK Medical Cannabis Registry.

British healthcare specialists may prescribe cannabis-based medicinal products to patients unresponsive to conventional medications. Investigators tracked variations from initial baseline levels in patient-reported outcomes at intervals of one, three, six, 12, 18, and 24 months. NORML reported that cannabis-based medicinal preparations aligned with previous findings, demonstrating statistically and clinically meaningful enhancements in sleep quality across every measured timepoint up to 24 months.

Study participants also experienced sustained improvements in their anxiety. Fewer than ten percent of participants reported adverse events from cannabis, all of which were mild, such as dry mouth.

“The consistent, clinically significant improvements in sleep quality demonstrated by this study support the potential therapeutic use of CBMPs for insomnia,” the study’s authors concluded.

“The results provide encouraging real-world evidence for the long-term utility of CBMPs,” they added. “This is particularly promising since current conventional therapies such as Z-drugs and benzodiazepines have shown limited long-term efficacy. … RCTs are required to assess the long-term use of CBMPs for insomnia further to determine their true efficacy.”

Additional observational research evaluating cannabis items among individuals registered in the UK Medical Cannabis Registry has indicated positive outcomes for individuals suffering from endometriosis, treatment-resistant epilepsy, cancer-related pain, anxiety, hypermobility disorders or Ehlers-Danlos syndrome, inflammatory bowel disease, insomnia, migraine, multiple sclerosis, osteoarthritis, substance use disorders, and inflammatory arthritis.

Full text of the study, “UK Medical Cannabis Registry: A two-year prospective observational cohort study of clinical outcomes in insomnia,” appears in Neuropsychopharmacology Reports. Additional information on cannabis and insomnia is available from NORML’s publication, Clinical Applications for Cannabis & Cannabinoids.

British healthcare specialists may prescribe cannabis-based medicinal products to patients who are unresponsive to conventional medications. Patients are then enrolled in the UK Medical Cannabis Registry for longitudinal monitoring.

Fewer than ten percent of participants reported adverse events from cannabis use. All recorded events were mild, including side effects such as dry mouth.

Established in 2019 by Curaleaf Clinic physicians in response to calls from NHS England and the National Institute for Health and Care Excellence, the UK Medical Cannabis Registry was created to address the evidence gap that followed the 2018 law change permitting specialist prescriptions.

Other observational studies from the registry report benefits for endometriosis, treatment-resistant epilepsy, cancer-related pain, inflammatory bowel disease, migraine, multiple sclerosis, and osteoarthritis.

About the author: Health Desk

Health Desk at Archynewsy.